346 related articles for article (PubMed ID: 11702115)
41. [18F FDG PET- applications in oncology].
Răileanu I; Rusu V; Stefănescu C; Cinotti L
Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):638-45. PubMed ID: 12092212
[TBL] [Abstract][Full Text] [Related]
42. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
43. Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients.
Tagliabue L; Del Sole A
Eur J Intern Med; 2014 Jan; 25(1):6-11. PubMed ID: 23910561
[TBL] [Abstract][Full Text] [Related]
44. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
[TBL] [Abstract][Full Text] [Related]
45. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Esophageal cancer].
Noboru O
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):265-9. PubMed ID: 12073632
[TBL] [Abstract][Full Text] [Related]
46. The clinical value of 18F-FDG detection with a dual-head coincidence camera: a review.
Ak I; Blokland JA; Pauwels EK; Stokkel MP
Eur J Nucl Med; 2001 Jun; 28(6):763-78. PubMed ID: 11440038
[TBL] [Abstract][Full Text] [Related]
47. F-18-FDG positron imaging in oncological patients: gamma camera coincidence detection versus dedicated PET.
Zimny M; Kaiser HJ; Cremerius U; Sabri O; Schreckenberger M; Reinartz P; Büll U
Nuklearmedizin; 1999; 38(4):108-14. PubMed ID: 10392375
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
49. Thoracic FDG PET: state of the art.
Erasmus JJ; McAdams HP; Patz EF; Goodman PC; Coleman RE
Radiographics; 1998; 18(1):5-20. PubMed ID: 9460106
[TBL] [Abstract][Full Text] [Related]
50. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of FDG-PET in malignant lymphoma.
Becherer A; Jaeger U; Szabo M; Kletter K
Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
[TBL] [Abstract][Full Text] [Related]
52. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
53. Relevance of positron emission tomography (PET) in oncology.
Weber WA; Avril N; Schwaiger M
Strahlenther Onkol; 1999 Aug; 175(8):356-73. PubMed ID: 10481766
[TBL] [Abstract][Full Text] [Related]
54. A review of the literature for whole-body FDG PET in the management of patients with melanoma.
Schwimmer J; Essner R; Patel A; Jahan SA; Shepherd JE; Park K; Phelps ME; Czernin J; Gambhir SS
Q J Nucl Med; 2000 Jun; 44(2):153-67. PubMed ID: 10967625
[TBL] [Abstract][Full Text] [Related]
55. [Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer].
Demura Y; Mizuno S; Wakabayashi M; Totani Y; Okamura S; Ameshima S; Ishizaki T; Miyamori I; Ito H; Yonekura Y
Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):676-81. PubMed ID: 11109804
[TBL] [Abstract][Full Text] [Related]
56. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
[TBL] [Abstract][Full Text] [Related]
57. [Positron-emission tomography in oncology].
Zaplatnikov K; Menzel C; Döbert N; Diehl M; Hamscho N; Grünwald F
Klin Med (Mosk); 2003; 81(12):13-21. PubMed ID: 14971150
[TBL] [Abstract][Full Text] [Related]
58. [18F FDG PET-Applications in Oncology].
Răileanu I; Rusu V; Stefănescu C; Cinotti L; Hountis D
Rev Med Chir Soc Med Nat Iasi; 2002; 106(1):14-23. PubMed ID: 12635354
[TBL] [Abstract][Full Text] [Related]
59. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma.
Stokkel MP; Draisma A; Pauwels EK
J Cancer Res Clin Oncol; 2001 May; 127(5):278-85. PubMed ID: 11355142
[TBL] [Abstract][Full Text] [Related]
60. Clinical applications of (18)F-FDG in oncology.
Nabi HA; Zubeldia JM
J Nucl Med Technol; 2002 Mar; 30(1):3-9; quiz 10-1. PubMed ID: 11948260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
